Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NVAX
stocks logo

NVAX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
90.26M
+2.21%
-0.549
+5.64%
114.53M
-82.82%
-0.315
-110.75%
128.15M
-46.43%
-0.120
-119.35%
Estimates Revision
The market is revising Upward the revenue expectations for Novavax, Inc. (NVAX) for FY2025, with the revenue forecasts being adjusted by 0.9% over the past three months. During the same period, the stock price has changed by -13.16%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.9%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-3.27%
In Past 3 Month
Stock Price
Go Down
down Image
-13.16%
In Past 3 Month
Wall Street analysts forecast NVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVAX is 11.25 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast NVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVAX is 11.25 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
1 Hold
3 Sell
Hold
Current: 6.860
sliders
Low
6.00
Averages
11.25
High
19.00
Current: 6.860
sliders
Low
6.00
Averages
11.25
High
19.00
JPMorgan
Underweight
downgrade
$7 -> $6
2025-11-18
Reason
JPMorgan
Price Target
$7 -> $6
2025-11-18
downgrade
Underweight
Reason
JPMorgan lowered the firm's price target on Novavax to $6 from $7 and keeps an Underweight rating on the shares. The firm sees limited commercial upside for the company with no material pipeline catalysts next year.
B. Riley
B. Riley
Buy
downgrade
$18 -> $16
2025-11-11
Reason
B. Riley
B. Riley
Price Target
$18 -> $16
2025-11-11
downgrade
Buy
Reason
B. Riley lowered the firm's price target on Novavax to $16 from $18 and keeps a Buy rating on the shares following the Q3 report. The firm highlights the company's increasingly diversified revenue streams.
B. Riley
B. Riley
Buy
downgrade
$18 -> $16
2025-11-10
Reason
B. Riley
B. Riley
Price Target
$18 -> $16
2025-11-10
downgrade
Buy
Reason
B. Riley lowered the firm's price target on Novavax to $16 from $18 and keeps a Buy rating on the shares. Novavax's Q3 top and bottom line results were ahead of the Street's expectations, driven by increasingly diversified revenue streams, the analyst tells investors in a research note. The earlier-stage pipeline represents a second engine of value creation, notably four active programs -- C. difficile, shingles, RSV combination, and pandemic flu, the firm adds.
TD Cowen
Hold
downgrade
$8 -> $7
2025-11-04
Reason
TD Cowen
Price Target
$8 -> $7
2025-11-04
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on Novavax to $7 from $8 and keeps a Hold rating on the shares. The firm updated its model ahead of Q3 results to reflect recent industry data and company updates. Positive P1/2 update for NVAX + SNY COVID-19/flu combo is encouraging, although latest U.S. Rx trends suggest declining COVID-19 vaccine market will be near-term headwind.
Cantor Fitzgerald
Overweight
initiated
$18
2025-10-24
Reason
Cantor Fitzgerald
Price Target
$18
2025-10-24
initiated
Overweight
Reason
Cantor Fitzgerald initiated coverage of Novavax with an Overweight rating and $18 price target. Novavax, known for developing Nuvaxovid, a protein-based COVID-19 vaccine with Matrix-M approved in multiple geographies and the only protein-based COVID-19 vaccine available in the U.S., has shifted from a commercial model to a licensing model and seeks partnerships around novel vaccine candidates and the Matrix-M technology to generate significant upfront payments, milestones, royalties, and revenue, the analyst tells investors.
H.C. Wainwright
Sean Lee
Buy
maintain
$10 -> $11
2025-10-23
Reason
H.C. Wainwright
Sean Lee
Price Target
$10 -> $11
2025-10-23
maintain
Buy
Reason
H.C. Wainwright analyst Sean Lee raised the firm's price target on Novavax to $11 from $10 and keeps a Buy rating on the shares after the company reached an agreement for the transfer of a facility in Maryland to AstraZeneca. Novavax is expected to receive $60M in cash over the next couple of quarters, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Novavax Inc (NVAX.O) is -8.67, compared to its 5-year average forward P/E of -0.24. For a more detailed relative valuation and DCF analysis to assess Novavax Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.24
Current PE
-8.67
Overvalued PE
23.51
Undervalued PE
-23.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-12.45
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
49.97
Undervalued EV/EBITDA
-74.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.62
Current PS
0.00
Overvalued PS
4.75
Undervalued PS
0.50
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

NVAX News & Events

Events Timeline

(ET)
2025-12-02
06:20:00
Kennedy Advisers Consider Major Revisions to Childhood Vaccination Schedule
select
link
2025-12-01 (ET)
2025-12-01
11:20:00
BofA Maintains $6 Price Target on Novavax Amid Negative Vaccine News
select
2025-12-01
09:11:00
Markets Cautiously Await Fed's Powell Speech Amid Rate Cut Expectations
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-01Barron's
Moderna and Novavax Shares Decline Following FDA's Suggestion for Tighter Vaccine Approval Standards

  • Vaccine Makers' Stock Reaction: Shares of vaccine manufacturers declined on Monday following news of potential regulatory changes.

  • FDA's Internal Memo: The Food and Drug Administration indicated it would implement stricter rules for vaccine approvals.

[object Object]
Preview
9.0
11-30WSJ
FDA Official Commits to Updated Vaccine Standards

  • FDA's New Approach: The Food and Drug Administration is changing its strategy for immunizations related to respiratory illnesses, including flu vaccines.

  • Concerns Over Covid Vaccine: The shift in strategy follows a report from vaccines division director Dr. Vinay Prasad, indicating that 10 children died after receiving the Covid vaccine, although specific evidence or details were not provided.

[object Object]
Preview
2.0
11-22SeekingAlpha
Novavax rebounds following a week-long decline

  • Stock Performance: Novavax (NVAX) saw a 3.70% increase in stock price, closing at $6.45, ending a seven-session losing streak despite a significant decline in the previous weeks.

  • Profitability Outlook: The company anticipates reaching profitability by 2028, contingent on upcoming vaccine launches in partnership with Sanofi, while also adjusting its revenue outlook despite a wider quarterly loss.

  • Investor Concerns: A major shareholder is urging for changes due to slow vaccine uptake and the company's struggle to convert scientific advancements into commercial success, prompting a review of options by the board.

  • Analyst Ratings: Seeking Alpha rates NVAX as Hold with mixed scores, while Wall Street analysts show a divided opinion with five recommending Strong Buy and others suggesting Hold or Sell, reflecting ongoing challenges as shares remain down 18.78% year-to-date.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Novavax Inc (NVAX) stock price today?

The current price of NVAX is 6.86 USD — it has increased 0.29 % in the last trading day.

arrow icon

What is Novavax Inc (NVAX)'s business?

Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.

arrow icon

What is the price predicton of NVAX Stock?

Wall Street analysts forecast NVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVAX is 11.25 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Novavax Inc (NVAX)'s revenue for the last quarter?

Novavax Inc revenue for the last quarter amounts to 70.45M USD, decreased -16.64 % YoY.

arrow icon

What is Novavax Inc (NVAX)'s earnings per share (EPS) for the last quarter?

Novavax Inc. EPS for the last quarter amounts to -1.25 USD, increased 64.47 % YoY.

arrow icon

What changes have occurred in the market's expectations for Novavax Inc (NVAX)'s fundamentals?

The market is revising Upward the revenue expectations for Novavax, Inc. (NVAX) for FY2025, with the revenue forecasts being adjusted by 0.9% over the past three months. During the same period, the stock price has changed by -13.16%.
arrow icon

How many employees does Novavax Inc (NVAX). have?

Novavax Inc (NVAX) has 952 emplpoyees as of December 05 2025.

arrow icon

What is Novavax Inc (NVAX) market cap?

Today NVAX has the market capitalization of 1.11B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free